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Abstract
Severe pneumonia remains an important cause of morbidity and mortality. Polymerase chain reaction (PCR) has been
shown to be more sensitive than current standard microbiological methods – particularly in patients with prior antibiotic
treatment – and therefore, may improve the accuracy of microbiological diagnosis for hospitalized patients with
pneumonia. Conventional detection techniques and multiplex PCR for 14 typical bacterial pneumonia-associated pathogens
were performed on respiratory samples collected from adult hospitalized patients enrolled in a prospective multi-center
study. Patients were enrolled from March until September 2012. A total of 739 fresh, native samples were eligible for
analysis, of which 75 were sputa, 421 aspirates, and 234 bronchial lavages. 276 pathogens were detected by microbiology
for which a valid PCR result was generated (positive or negative detection result by Curetis prototype system). Among
these, 120 were identified by the prototype assay, 50 pathogens were not detected. Overall performance of the prototype
for pathogen identification was 70.6% sensitivity (95% confidence interval (CI) lower bound: 63.3%, upper bound: 76.9%)
and 95.2% specificity (95% CI lower bound: 94.6%, upper bound: 95.7%). Based on the study results, device cut-off settings
were adjusted for future series production. The overall performance with the settings of the CE series production devices
was 78.7% sensitivity (95% CI lower bound: 72.1%) and 96.6% specificity (95% CI lower bound: 96.1%). Time to result was
5.2 hours (median) for the prototype test and 43.5 h for standard-of-care. The Pneumonia Application provides a rapid and
moderately sensitive assay for the detection of pneumonia-causing pathogens with minimal hands-on time.
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Introduction
Bacterial infection of the respiratory tract is the most common
source of severe sepsis and septic shock in intensive care patients,
and is one of the leading causes of death in this population. In
Europe and in the U.S., the incidence of pneumonia is 1 to 5 cases
per 1,000 individuals in the general population, depending on
various factors like e.g. age or underlying diseases, respectively [1–
4]. One of the hardest challenges in modern infectious disease
treatment is continuously increasing resistance against anti-
microbial agents resulting in frequent inappropriate empiric
treatment and subsequently increased mortality [5]. The current
guideline-driven strategy for empirical antimicrobial therapy in
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ICU patients harbours the risk for selecting antibiotic-resistant
pathogens as well as being potentially insufficient for the individual
patient [6–9]. Reasons for an inappropriate treatment may include
insufficient coverage of the underlying pathogen because of
primary or acquired resistance. For ventilator-associated pneumo-
nia (VAP), the mortality rate exceeded 50% when the initial
antibiotic therapy was inappropriate [10]. This number dropped
to 33% when an appropriate antibiotic therapy was initially
administered and was associated with a shorter duration for
mechanical ventilation and a shorter ICU stay [11]. A faster
diagnostic workup using molecular methods could be one option
to reduce the fatal consequences of inappropriate antimicrobial
therapy.
Conventional diagnostics of pathogen and resistance determi-
nation still rely on culture-based methods. However, these
techniques have certain limitations (e.g. not cultivable microor-
ganisms, decreased sensitivity in patients with prior antibiotic
treatment – a frequent constellation on patients admitted to the
ICU) and results are only available after one to two days after
inoculation as preliminary reports, leaving correct initial antimi-
crobial therapy to chance. A recent study showed impressively that
treatment guided by microbiological results is superior to a broad
based empiric treatment in stable patients [12]. However, in
instable patients guided treatment is not possible because fast
point-of-care tests delivering results immediately are not yet
available. Furthermore, the microbiological outcome is very
sensitive to pre-analytical specimen handling and to the patient’s
pre-treatment with antimicrobials. Culture-independent molecular
biology-based techniques such as PCR present a possibility to
improve patient care. Recent studies in septic patients have
demonstrated the potential power of multiplexed molecular testing
approaches [13–15].
Herein we report the results of a clinical evaluation regarding a
prototype system, a novel platform for multiplex molecular
diagnostic determination of pathogens and resistance markers
causing severe pneumonia - mostly bacterial infections. The
objectives of this multicenter study were (1) to test a prototype of
the multiplex PCR test under clinical conditions in order to adjust
and validate cut-offs of this device, and (2) compare the pathogen
detection performance of the device with conventional microbi-
ological techniques in patients with suspected lower respiratory
tract infection.
Material and Methods
Trial design
The trial was a prospective, non-interventional, non-random-
ized, multicenter clinical trial conducted at the following 5
European sites (in brackets: accreditation number): University
Hospital Tu¨bingen, Germany (D-ML-13130-01-00); University
Hosptial Bochum/Bad Oeynhausen, Germany (DGA-ML-
6638.09.02); Hoˆpital Erasme-Universite´, Brussels, Belgium (BE-
LAC 245-MED); Hospital Clı´nic Villarroel, Barcelona, Spain
(ER-0186/2007), and University Hospital Jena, Germany (D-ML-
13144-02-00). All laboratories are certified and follow European
guidelines for microbiology testing. As the test is intended to be
used in critically ill patients, who have a particularly increased
mortality risk in case of inappropriate treatment, only hospitalized
patients were targeted.
The protocol for this trial and supporting CONSORT checklist
are available as Checklist S1 and Protocol S1.
The study compared the Pneumonia Application (prototype
devices, Curetis AG, Holzgerlingen, Germany) against current
standard-of-care methods for pathogen detection, for 14 patho-
gens out of a total of 17 pathogens included in the multiplex panel:
Acinetobacter baumannii, Enterobacter spp., Escherichia coli,
Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumo-
niae, Moraxella catarrhalis, Morganella morganii, Proteus spp.,
Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus
aureus, Stenotrophomonas maltophilia, and Streptococcus pneumo-
niae. For the three atypical pathogens on the multiplex panel,
Chlamydia pneumoniae, Legionella pneumophila, and Pneumocys-
tis jirovecii, reference tests were only done if requested by the
treating physician. Data were therefore excluded from this report.
Patient enrolment, study protocol and oversight
Samples from hospitalized adult (.18y) patients with clinical
suspected pneumonia without or with antibiotic treatment were
enrolled from March through September 2012. Randomly
selected native respiratory samples (sputum, tracheal aspirate,
bronchoalveolar lavage [BAL]) with a left-over volume of at least
1 ml were included when accepted for standard-of-care microbi-
ology testing. Specimens were excluded in case of any of the
following: Not accepted for analysis by standard-of-care, if the
prototype test could not be performed on the same day as the start
of microbiological testing, known tuberculosis infection, previous
analysis with the prototype Application of a sample from the same
patient within the past 5 days, sample type other than those
mentioned above, if sample storage time has exceeded 18 hours
after arrival in the laboratory.
Patient identification was removed from specimens and samples
were coded (pseudonymised) and split into three aliquots prior to
testing with the prototype; one aliquot was used for routine
microbiology, one for testing with the prototype, and the third
aliquot was stored frozen (at220uC or colder) for discrepant result
resolution done at Curetis after the end of enrolment (see below).
The sampling was not trial-related and took place only when
medically indicated. The prototype test was performed on the
same day as the start of standard-of-care testing. Prototype test
results were not used for diagnosis, treatment or other patient
management decisions. Quality assurance, monitoring, and data
management was conducted by a CRO (Contract Research
Organization), contracted by Curetis AG, the study sponsor. Study
personnel was bound to confidentiality and trained by the CRO
and Curetis.
Ethics statement
The clinical study was initially reviewed and approved by the
ethics committee of the Eberhard Karls-University Tu¨bingen,
Germany (309/2011A), and afterwards by the institutional ethics
committees of the other study sites, separately. The study was
conducted in accordance with the Declaration of Helsinki and
ICH-GCP. With the exception of the Barcelona clinic, 4 of 5
committees waived the need for informed consent as no additional
patient samples were needed to perform this purely observational
study. Signed written informed consent to participate in this
clinical trial was obtained at the Barcelona clinic as required by
Spanish law.
Statistical methods
Sensitivity, specificity, and positive and negative predictive
values were calculated by comparison of microbiological results for
the 14 cultivable bacterial species to the prototype results and done
by the Curetis. 95% confidence intervals were calculated
according to the Wilson Score Method [16]. ’True positive’ and
’true negative’ (subsequently ‘‘TP’’ and ‘‘TN’’) were defined as
positive (negative) in microbiological standard method and positive
(negative) in the prototype Application. Accordingly, ’false
Multiplex PCR for Pathogens in Severe Pneumonia
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positive’ and ’false negative’ (subsequently ‘‘FP’’ and ‘‘FN’’) were
defined as positive (negative) in the prototype Application but
negative (positive) in the standard method.
Laboratory Methods
Standard-of-care methods. Standard of care microbiology
was performed according to the Standard Operating Procedures
(SOP) at each study site. All laboratories were quality assured
according to ISO 15189. Respiratory tract samples were cultured
on non-selective and selective culture media, identification of
bacterial species was conducted biochemically or by mass-
spectrometry. Each cultured bacterial isolate was stored at
280uC and sent to the Curetis for discrepant result resolution
according to the study protocol. Microbiological results as well as
patient data were transferred to an electronic case report form
(eCRF) by the investigators. Investigational device raw data were
sent to the CRO electronically. Non-panel pathogens were not
reported from all sites consistently.
Prototype multiplex test. The assay detects 16 bacterial and
one fungal species known to cause pneumonia, as well as 20
genetic markers (by 22 primer pairs) coding for antibiotic
resistances (not reported here). The prototype Pneumonia
Application was used as recommended by the manufacturer.
Briefly, 180 ml of the specimen were transferred into a sample
tube. Sample lysis comprised a 30 minute protocol including
mechanical, thermal, chemical and enzymatic sample treatment.
The lysed sample was further processed in a prototype Cartridge.
The Cartridge was pre-loaded with reagents for DNA purification,
PCR primers and probes for array hybridization. The prototype
Pneumonia Application integrated and automated sample lysis,
genomic DNA purification, multiplex nucleic acid amplification by
end-point PCR using fluorescence-labelled primers in eight
independent PCR chambers with individual detection array, and
qualitative amplicon detection by hybridization on a porous array
membrane. The lysis protocol employed by the instrument is
proprietary (patent pending). PCR and array hybridization was
performed with at least three probes per analyte. A series of images
of the hybridisation procedure over a specific temperature range is
taken by a CCD camera. Results were derived from images
processed by the proprietary software prototype. An internal
control (a synthetic gene, without significant homology to known
sequences) was co-processed in every PCR chamber to verify DNA
purification, PCR and array hybridization. Statistical analysis of
the performance data was conducted using only measurements of
valid PCR chambers. Time-to-result (TTR) for the prototype test
was calculated from start of the Lysator until availability of the
result. Figure 1 provides an overview of the analytical procedure.
Discrepant Result Resolution. For all FP detections saved
array images from respective prototype runs were visually screened
for the presence of true positive hybridization signals. For FP
detections with verified signals and for all FN detections a
discrepant result resolution test was performed from the sample
left-overs. In short, 180 ml of sample was treated with Proteinase K
(Qiagen, Hilden, Germany) (10 min) and heated to 95uC (15 min);
DNA was then isolated using the QiaAmp DNA Blood Mini Kit
(Qiagen) according to the manufacturer’s recommendations. DNA
was amplified in single-plex PCRs with primers used in the
prototype device. Amplicons were sequenced bi-directionally by a
third party laboratory and identities were confirmed by
‘‘BLASTn’’ analysis as recommended [17]. False positive S.
pneumoniae assay hits were confirmed by amplification of
additional PCR targets against four pneumococcal marker genes
(cpsA, lytA, rpoB, ply) [18–23].
Results
Patients
Figure 2 provides an overview on enrolment and samples.
Patient age ranged from 19 to 95 years with a median of 64 years
(mean 6 std. dev: 62.5615.5 years). 523 samples were from male
patients, 216 from females. The majority of samples (617 of 739)
were collected from ICU patients. Of the 739 samples taken for
analysis, 227 samples were positive by standard-of-care microbi-
ology for (non-atypical) pathogens of the prototype panel (31%). In
these 227 samples 276 prototype panel pathogens could be
detected by culture. Additional pathogens, not covered by the
prototype panel, were identified by standard-of-care microbiology,
see footnote in Table 1. Results of atypical pathogens have been
excluded from statistical analysis due to lack of standardisation of
the reference methods at the different study sites.
Device Performance
Analysis of the prototype run validity, corresponding to results
from the eight PCR chambers in each cartridge, yielded 65.7%
valid measurements. The reasons identified for invalid results
within successful runs were grid failures (4.9%), pumping failures
(5.6%), and control gene failures (23.8%). ‘Grid failures’ occured
when the hybridization array was not correctly identified by the
detection software. ‘Pumping failures’ were either caused by
insufficient washing during hybridization or inadequate buffer
distribution to PCR chambers. ‘Control gene failures’ were caused
by either failure to obtain a DNA eluate, PCR failure or by fluidic
failures. TTR for the prototype test yielded a median of 5.2 hours
(1st and 3rd quartile 5.1 and 5.3 hours). The TTR median for
standard-of-care was 43.5 h (1st and 3rd quartile 25.2 and
70.1 hours) for pathogen identification.
Valid chamber results were generated for 170 of the 276
pathogens detected by microbiology (positive or negative detection
result by multiplex prototype assay). Among these, 120 pathogens
were identified by the prototype device, 50 pathogens were not
detected (Table 1). Overall performance for pathogen identifica-
tion was 70.6% sensitivity (95% CI lower bound: 63.3%, upper
bound: 76.9%, and 95.2% specificity (95% CI lower bound:
94.6%, upper bound: 95.7%). As shown in Table 1 sensitivity
strongly depends on the bacterial species. Notably, while the PPV
varied between 2.0% for S. pneumoniae and 100% for K.
pneumoniae the NPV reached .96% for all pathogens of the
panel within the study population of the five study sites.
Discrepant (FP and FN) results were resolved as described in
Material and Methods. 50 pathogens (FN) were not detected by
the prototype of which 36 were confirmed by subsequent positive
PCR/sequencing results as false negative. 14 pathogens could not
be detected in the manual retesting.
Vice versa, the prototype assay detected additional 317
pathogens, of which 184 were confirmed by PCR/sequencing
demonstrating their presence in the sample. Of 133 non-
confirmed detections, 48 corresponded to array image artefacts
(either caused by insufficient washing, or particles on the
membrane or software analysis errors). In one case the initially
identified Enterobacter spp. could not be confirmed by the manual
PCR/sequencing procedure. BLASTn analysis revealed the
presence of K. pneumoniae DNA in the sample indicating a cross
reaction the primer pair used in the assay.
Most remarkable was the high number of false positive S.
pneumoniae detections (N = 98) of which 29 were not reproducible
by single-plex PCR. The remaining 69 cases could not be clearly
assigned to specific streptococcal species by BLASTn analysis of
sequenced PCR products due to insufficient database coverage
Multiplex PCR for Pathogens in Severe Pneumonia
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and variability of the sequenced DNA fragment, but showed
similarities to the members of to the Streptococcus mitis group. For
further analysis of this special issue 4 additional PCR targets
demonstrating pneumococcal marker genes (cpsA, lytA, plyA,
rpoB) were chosen and amplified. Finally, 5 of 69 initial detections
were confirmed by a positive result in all 4 additional PCRs as ‘‘S.
pneumoniae’’.
The results from this study with the prototype device were taken
to improve the performance of the next generation of the
Pneumonia Application by the company. In detail, the detection
of washing failures, the adaptation of melting temperature ranges,
and cut-off changes to optimize sensitivity and specificity were
adjusted. Changed parameters were collected and validated using
the pool of the described study data. Raw data were stored as
series of images from each reaction chamber of each run, thus it
was possible to re-analyze and re-calculate the complete data pool
using the new settings without changing the obtained original data.
Both overall sensitivity and specificity were increased after re-
calculation (sensitivity: 78.7%; 95% CI lower bound of 72.1%,
Figure 1. (a) Load sample tube, (b) insertion of sample tube into the Lysator, (c) transfer of sample tube and Master Mix into the
Cartridge, (d) insertion of Cartridge into the Analyzer, (e) display of results.
doi:10.1371/journal.pone.0110566.g001
Figure 2. Overview on enrolment and samples for analysis.
doi:10.1371/journal.pone.0110566.g002
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upper bound: 84.0%, and specificity: 96.6%; 95% CI lower bound
of 96.1%, upper bound: 97.0%) (data not shown).
Furthermore, re-testing of 123 study sample left-overs on
commercial CE-marked Unyvero devices with improved settings
confirmed the results obtained by re-calculation of the study data
pool (data not shown).
Conclusions
Pneumonia Application testing of respiratory samples is a rapid
approach to detect clinically relevant pneumonia-causing patho-
gens in a fully automated manner. The panel of detectable
pathogens was chosen according to pathogens relevance in
multicenter studies on pneumonia and after expert consultations
[24]. As demonstrated in the European multicenter study,
sensitivity for in-panel organisms varies greatly in the prototype
devices, reaching 100% for 4/17 pathogens and 70.6% overall.
The prototype device detected 184 additional pathogens ( =
confirmed FP) in the study samples after discrepant results
resolution in comparison to standard-of-care methods. Samples
included in the study were mainly (83.5%) collected from ICU
patients due to the study centers being tertiary care teaching
hospitals with a case-mix of multi-morbid patients and solid-organ
transplant recipients. As expected, more gram-negative Entero-
bacteriaceae such as E. coli and non-fermenters such as P.
aeruginosa were detected in our study patient population than in a
setting with non-pretreated patients with community-acquired
pneumonia. According to our study data, a high proportion of the
patients were pretreated with antibiotics (pre-treated 47,8% of
patients, not pre-treated 5,3%, unknown 47,0%), which may in
part explain the discrepancy between pathogens detected by the
prototype but not found in culture. The high number of ‘‘false
positive’’ for streptococci, H. influenzae, and M. catarrhalis could
reflect an asymptomatic carriage with a normal oro-pharyngeal
flora, which was not reported by the standard culture. Another
explanation would be amplification of DNA of dead microbial
organisms, which were not relevant for the patient’s course of
disease. Extensive discrepant results resolution enabled us to gain
insight into the potential causes: In a re-sequencing analysis
applying in-test PCR primers and conditions demonstrated that
69/98 samples with positive S. pneumoniae test result contained
streptococcal DNA of either S. pneumoniae (of which 5 could be
confirmed by additional PCR targets) or non S. pneumoniae
streptococci. Using BLASTn analyses on the GenBank database
amplicon sequences of the primary PCR allowed no distinction of
S. pneumoniae sequence-type and nearly related S. mitis group
sequences. According to previous studies, molecular detection and
identification of S. pneumoniae is challenging because neither a
single PCR target (e.g. pylA) is present in all strains nor is a single
target specific for S. pneumoniae (e.g. 16S rRNA gene, rrs) [25].
On the other hand differentiation of S. mitis group streptococci
also causes problems in clinical microbiology laboratories, which
could explain the microbiology confirmed S. pneumoniae showing
only weak signals with the comparative S. pneumoniae PCRs.
Nucleic acid amplification techniques cannot differentiate
between living and dead organisms. This might explain a
proportion of positive detection results in the PCR test in
comparison to cultivation-based techniques. Previous studies
examining blood-stream infections by PCR methods allowed
detection of bacterial DNA up to 60 days after initiation of
antimicrobial therapy [26]. Persistence of amplifiable microbial
DNA in respiratory samples of pre-treated pneumonia patients has
not been examined in previous studies for all in-panel organisms.
After data re-analysis using production-device settings only 38
false-negative PCR results were generated for in-panel organisms.
When comparing our data to previous multiplex PCR test related
studies for respiratory samples, comparable sensitivity and
specificity results were obtained for bacterial pathogens [27,28].
Negative predictive values between 98.2 and 100% illustrate the
strength of the test to confirm absence of in-test organisms.
In summary, the Curetis Pneumonia Application is the first
fully-automated multiplex PCR-based diagnostic device entering
the market. We have assessed performance of a prototype in a
prospective multi-center study using routine respiratory samples.
The assay has several critical advantages over conventional nucleic
acid-amplification tests, which have been licensed in the last 20
years. The Pneumonia Application is simple to perform, is not
prone to cross-contamination, requires minimal biosafety facilities
and has a moderate to high sensitivity of up to 100% for in-panel
organisms. However, we could demonstrate that the prototype
devices have specificity issues regarding Enterobacter spp., H.
influenzae and S. pneumoniae in comparison to culture-based
methods. Specificities for all 3 organisms were distinctly increased
with the cut-off settings of the series production devices. Although
739 patient samples have been measured throughout the study,
insufficient case numbers have been obtained for statistical analysis
of the 22 resistance genes on the panel. Due to the use of prototype
instruments in the study and the manual manufacturing of the
consumables, a significant rate of invalid test runs has occurred.
Test turn-around times for the instrumentation were remarkably
short. This is adding much to the impact of microbial testing for
clinical treatment decisions. Routine microbial testing in commu-
nity-acquired pneumonia patients is not yet recommended by
guidelines as standard of care particularly for out- patients mainly
due to long test turn-around times [29]. For further application,
the study allowed recalculation of detection signal limits and
revision of the software interpretation algorithms already improv-
ing sensitivity and specificity values in an in silico re-analysis of the
study raw data.
Early detection of additional causative pathogens by a sensitive
PCR-based method has the potential to reduce the proportion of
patients with initial inappropriate treatment [5]. In contrast,
detection of non-causative microorganisms may promote antibi-
otic overuse. Clinical relevance depends on detected concentra-
tions and origin of specimens, e.g sputum or lavage. Furthermore,
some microorganisms may be part of the normal flora of healthy
individuals, like e.g. streptococci or H. influenzae, whereas others
are regarded as disease relevant, even when present in trace
amounts.
The investigational system is intended to support treatment of
severely ill patients where rapid appropriate treatment instead of
empirical antibiotic regimens is absolutely essential. For these
patient cohorts, the benefits of rapid and sensitive detection will
presumably overweigh disadvantages of potential antibiotic
overuse. PCR-based results together with other diagnostic data
and the clinical appearance of the patient will support the
physician to define optimal treatments much more rapidly than by
conventional methods alone. A full-cost calculation covering
standard microbiological workup including microscopy and
culture in comparison to molecular testing cannot be given, as
the device under examination was a prototype instrument without
given price list for consumables. We expect, that the molecular test
in the final product may be more costly as culture based methods.
The potential improvement of care by such a system lies
primarily in the early detection of pathogens that are not covered
by empiric treatment recommended in guidelines. However,
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clinical benefit of such a new method needs to be demonstrated in
additional studies.
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